Amino pyrimidine compound for inhibiting protein tyrosine kinase activity

The compound of formula (III-a):

• wherein,
• R1 is selected from H, halo, —CN, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C3-C6 carbocyclyl;
• R2 is selected from optionally substituted C1-C6 alkoxy or optionally substituted C1-C6 haloalkoxy;
• R11 is selected from H, halo, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl or optionally substituted C1-C6 alkoxy;
• R12 is selected from H, or C1-C6 alkyl;
• R13 is optionally substituted C1-C6 alkyl;
• or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, or an isotopically labeled compound thereof.

The compound of formula (III-c):

• wherein,
• R1 is selected from H, halo, —CN, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy or optionally substituted C3-C6 carbocyclyl;
• R2 is selected from optionally substituted C1-C6 alkoxy or optionally substituted C1-C6 haloalkoxy;
• R7 is selected from H, or optionally substituted C1-C6 alkyl;
• R11 is selected from H, halo, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 haloalkyl or optionally substituted C1-C6 alkoxy;
• R12 is independently selected from H, halo, —CN, —NO2, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C6 carbocyclyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio or optionally substituted C1-C6 haloalkoxy, as long as the chemistry permits;
• wherein the said optionally substituted groups are optionally further substituted by 1, 2, 3, 4, 5, 6, 7, or 8 deuteriums;
• R13 is selected from H, halo, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 haloalkyl or optionally substituted C1-C6 alkoxy;
• wherein the said optionally substituted groups are optionally further substituted by 1, 2, 3, 4, 5, 6, 7, or 8 deuteriums;
• or R12 and R13 could be taken together to form optionally substituted 5- to 8-membered heterocyclyl, or optionally substituted 5- to 10-membered heteroaryl;
• R14 is selected from H, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 haloalkyl;
• R15 is selected from —OH, —CN, —NO2, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or NR8R9;
• wherein R8 and R9 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl or optionally substituted C3-C6 carbocyclyl, or R8 and R9 together with the nitrogen atom to which they are attached form optionally substituted 4- to 6-membered heterocyclyl;
• or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, or an isotopically labeled compound thereof.